Thoratec Corporation (Thoratec), a company developing medical technologies to improve patient survival and quality of life, has planned to webcast its investor event to discuss data from the HeartMate II Destination Therapy clinical trial that will be presented during the clinical trial session at the American Heart Association(AHA) Scientific Sessions 2009.
The event will include a review of the trial data by Dr. Joseph Rogers of Duke University, who is presenting the data at AHA as a clinical trial, and comments from Gary F. Burbach, president and chief executive officer of Thoratec.